Market research
RENX.LSE Renalytix Plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- 88
- Dividend yield
- Not available
- Beta
- 1.81
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Health Information Services
- ISIN
- GB00BYWL4Y04
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- 88
- Dividend yield
- Not available
- Beta
- 1.81
About
About Renalytix Plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RENX.LSE discussion.
5 years, 4 months ago
Renalytix AI plc is currently in a long term uptrend where the price is trading 21.6% above its 200 day moving average.
From a valuation standpoint, the stock is 367.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2082.0.
Renalytix AI plc's total revenue rose by 281.0% to $400K since the same quarter in the previous year.
Its net income has dropped by 288.0% to $-9M since the same quarter in the previous year.
Finally, its free cash flow fell by 76.4% to $-5M since the same quarter in the previous year.
Based on the above factors, Renalytix AI plc gets an overall score of 2/5.